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Introduction:  The benefits of statins in reducing coronary events, strokes and death from all causes have been well established. They have 
not been shown to improve morbidity and mortality in patients with overt heart failure (HF). However the role of statins in preventing HF remains 
unproven.
Methods: MEDLINE was searched for all the prospective randomized controlled trials with an average follow up of at least one year comparing 
statins with placebo or usual care on the incidence of new onset or worsening HF. Overall estimates of effect were calculated using the fixed-effects 
model since heterogeneity amongst the studies was not significant.
Results: 8 studies were retrieved with the total population of 20,054 (79,233 person-years) for statins and 20,087 (79,374 person-years) for 
placebo/usual care. The risk of new onset or worsening HF was 24% lower in patients with known coronary artery disease (CAD) on statins compared 
to placebo/usual care group (p<0.00001). However there was no significant difference between the two groups in the reduction of new onset or 
worsening HF in patients at risk of CAD (p=0.98) or those who already have HF (p=0.93).
Conclusions: Statins are beneficial in preventing HF in patients with CAD but fail to provide benefits in those who do not have any evidence of 
CAD or those who have manifest HF. Too short a follow up may account for the lack of benefit in patients without CAD and too advanced disease 
progression may account for the lack of benefit in patients with manifest HF.
